Citigroup Inc. Boosts Stock Holdings in IQVIA Holdings Inc. $IQV

Citigroup Inc. raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 108.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 915,183 shares of the medical research company’s stock after acquiring an additional 475,557 shares during the quarter. Citigroup Inc. owned approximately 0.54% of IQVIA worth $173,830,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in IQV. Physician Wealth Advisors Inc. lifted its holdings in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. raised its position in shares of IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after buying an additional 101 shares during the last quarter. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA in the third quarter worth about $36,000. Asset Dedication LLC boosted its position in IQVIA by 224.0% during the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock worth $38,000 after acquiring an additional 168 shares during the last quarter. Finally, Rothschild Investment LLC grew its stake in IQVIA by 85.5% during the 2nd quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock valued at $42,000 after acquiring an additional 124 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE IQV opened at $165.63 on Friday. The stock has a fifty day simple moving average of $217.61 and a 200-day simple moving average of $208.44. The company has a current ratio of 0.75, a quick ratio of 0.70 and a debt-to-equity ratio of 2.09. The stock has a market cap of $28.11 billion, a PE ratio of 21.07, a P/E/G ratio of 1.59 and a beta of 1.37. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. IQVIA’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on IQV. JPMorgan Chase & Co. lowered their target price on IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Evercore restated an “outperform” rating and issued a $225.00 target price on shares of IQVIA in a report on Thursday, February 5th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Mizuho set a $266.00 price target on shares of IQVIA in a research report on Friday, January 9th. Finally, Jefferies Financial Group cut their price objective on shares of IQVIA from $270.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $235.20.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.